Engineering graded tissue interfaces

Interfacial zones between tissues provide specialized, transitional junctions central to normal tissue function. Regenerative medicine strategies focused on multiple cell types and/or bi/tri-layered scaffolds do not provide continuously graded interfaces, severely limiting the integration and biological performance of engineered tissue substitutes. Inspired by the bone-soft tissue interface, we describe a biomaterial-mediated gene transfer strategy for spatially regulated genetic modification and differentiation of primary dermal fibroblasts within tissue-engineered constructs. We demonstrate that zonal organization of osteoblastic and fibroblastic cellular phenotypes can be engineered by a simple, one-step seeding of fibroblasts onto scaffolds containing a spatial distribution of retrovirus encoding the osteogenic transcription factor Runx2/Cbfa1. Gradients of immobilized retrovirus, achieved via deposition of controlled poly(l-lysine) densities, resulted in spatial patterns of transcription factor expression, osteoblastic differentiation, and mineralized matrix deposition. Notably, this graded distribution of mineral deposition and mechanical properties was maintained when implanted in vivo in an ectopic site. Development of this facile and robust strategy is significant toward the regeneration of continuous interfacial zones that mimic the cellular and microstructural characteristics of native tissue.

[1]  Andrés J. García,et al.  Mineralization capacity of Runx2/Cbfa1-genetically engineered fibroblasts is scaffold dependent. , 2006, Biomaterials.

[2]  S. Woo,et al.  Biomechanics of knee ligaments: injury, healing, and repair. , 2006, Journal of biomechanics.

[3]  T. Wu,et al.  Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity , 2006, Cancer Gene Therapy.

[4]  J. L. Le Doux,et al.  Complexation of retrovirus with cationic and anionic polymers increases the efficiency of gene transfer. , 2001, Human gene therapy.

[5]  R. Langer,et al.  Drug delivery and targeting. , 1998, Nature.

[6]  Lonnie D Shea,et al.  Controlled release systems for DNA delivery. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  B. A. Byers,et al.  Effects of Runx2 genetic engineering and in vitro maturation of tissue-engineered constructs on the repair of critical size bone defects. , 2006, Journal of biomedical materials research. Part A.

[8]  Stephen B Doty,et al.  Development of controlled matrix heterogeneity on a triphasic scaffold for orthopedic interface tissue engineering. , 2006, Tissue engineering.

[9]  Jennifer L West,et al.  Covalently immobilized gradients of bFGF on hydrogel scaffolds for directed cell migration. , 2005, Biomaterials.

[10]  R. Guldberg,et al.  Inducible regulation of Runx2-stimulated osteogenesis , 2006, Gene Therapy.

[11]  I. E. Wang,et al.  Role of osteoblast–fibroblast interactions in the formation of the ligament‐to‐bone interface , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[12]  J. Andrish,et al.  A biomechanical comparison of different surgical techniques of graft fixation in anterior cruciate ligament reconstruction , 1987, The American journal of sports medicine.

[13]  Andrés J. García,et al.  Glucocorticoid-induced osteogenesis is negatively regulated by Runx2/Cbfa1 serine phosphorylation , 2006, Journal of Cell Science.

[14]  Makoto Sato,et al.  Targeted Disruption of Cbfa1 Results in a Complete Lack of Bone Formation owing to Maturational Arrest of Osteoblasts , 1997, Cell.

[15]  M. Yarmush,et al.  Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation. , 2004, Biophysical journal.

[16]  David J. Mooney,et al.  Spatio–temporal VEGF and PDGF Delivery Patterns Blood Vessel Formation and Maturation , 2007, Pharmaceutical Research.

[17]  D. Wei,et al.  In Vitro and In Vivo Synergistic Interactions Between the Runx2/Cbfa1 Transcription Factor and Bone Morphogenetic Protein‐2 in Stimulating Osteoblast Differentiation , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  Stavros Thomopoulos,et al.  Variation of biomechanical, structural, and compositional properties along the tendon to bone insertion site. , 2003, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[19]  Jeffrey Bonadio,et al.  Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration , 1999, Nature Medicine.

[20]  Robert E Guldberg,et al.  Effects of medium perfusion rate on cell-seeded three-dimensional bone constructs in vitro. , 2003, Tissue engineering.

[21]  Andrés J. García,et al.  Dermal fibroblasts genetically modified to express Runx2/Cbfa1 as a mineralizing cell source for bone tissue engineering. , 2007, Tissue engineering.

[22]  J. Briscoe,et al.  Morphogens and the Control of Cell Proliferation and Patterning in the Spinal Cord , 2007, Cell cycle.

[23]  David J. Mooney,et al.  Polymeric Growth Factor Delivery Strategies for Tissue Engineering , 2003, Pharmaceutical Research.

[24]  G. Karsenty,et al.  Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation , 1997, Cell.

[25]  Jennifer H. Elisseeff,et al.  Engineering Structurally Organized Cartilage and Bone Tissues , 2004, Annals of Biomedical Engineering.

[26]  David J. Mooney,et al.  DNA delivery from polymer matrices for tissue engineering , 1999, Nature Biotechnology.

[27]  M. Montcouquiol,et al.  Planar and Vertical Signals Control Cellular Differentiation and Patterning in the Mammalian Cochlea , 2003, The Journal of Neuroscience.

[28]  R. Golestanian,et al.  On the Landau-Levich transition. , 2007, Langmuir : the ACS journal of surfaces and colloids.

[29]  Hiromu Ito,et al.  Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy , 2005, Nature Medicine.